<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81932">
  <stage>Registered</stage>
  <submitdate>27/03/2007</submitdate>
  <approvaldate>30/03/2007</approvaldate>
  <actrnumber>ACTRN12607000188437</actrnumber>
  <trial_identification>
    <studytitle>A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer</studytitle>
    <scientifictitle>A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer to assess progression-free survival benefits</scientifictitle>
    <utrn />
    <trialacronym>ICON 7</trialacronym>
    <secondaryid>International Standard Randomized Controlled Trial Number (ISRCTN): ISRCYN91273375</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Research Arm: Carboplatin (Intravenously, AUC 6) plus paclitaxel (Intravenously, 175mg/m2) on day 1 every 3 weeks (one cycle) until disease progression or for a maximum of 6 cycles, with bevacizumab (intravenously, 7.5mg/kg) on day 1 every 3 weeks (one cycle) until disease progression or for a maximum of 18 cycles</interventions>
    <comparator>Control Arm: Carboplatin (Intravenously, AUC 6) plus paclitaxel (Intravenously, 175mg/m2) on day 1 every 3 weeks (one cycle) until disease progression or for a maximum of 6 cycles</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>At baseline, after Cycle 3, 6, 9 and 12, and every 6 months thereafter until disease progression.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Overall Survival (OS). </outcome>
      <timepoint>Timepoints: (before disease progression) 3 monthly during years 2 and 3, 6 monthly during years 4 and 5, then yearly; (after disease progression) 6 monthly during first 5 years, then yearly.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Response Rate and Duration of Response.</outcome>
      <timepoint>At baseline, after Cycle 3, 6, 9 and 12, and every 6 months thereafter until disease progression. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Toxicity. </outcome>
      <timepoint>Before each cycle, at safety follow-up visit (between week 56-58 since start of treatment, or between 4-6 weeks after last bevacizumab treatment, whichever occurs later; or between 4-6 weeks after date of progression if progression occurs less than 56 weeks from start of treatment), and toxicities related to study treatment continuing after the safety follow-up visit should be followed-up until resolved or relationship to treatment changed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Quality of life (QoL). </outcome>
      <timepoint>Before cycles 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18; then 15, 18, 21, 24 and 36 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Health Economics.</outcome>
      <timepoint>Before each cycle, then 3 monthly during years 2 and 3, 6 monthly during years 4 and 5, then yearly.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Translational (biomarker) Research. </outcome>
      <timepoint>Timepoints (depending on level of participation from each patient): at baseline, before cycles 1, 2 and 6, and at time of disease progression, after cycles 1 and 6, and at follow-up 3, 6 and 12 months after end of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Written informed consent and able to comply with the protocol2. Histologically confirmed:a. High risk International Federation of Gynecology and Obstetrics (FIGO) stage I and II a, with grade 3 or clear cell histology, epithelial ovarian cancerb. FIGO stage IIbIV (all grades, all histological types) epithelial ovarian cancerc. Fallopian tube or primary peritoneal cancer3. Patients fit enough to receive protocol treatment4. Urine dipstick for proteinuria &lt;2+ (if urine dipstick is &gt; or = 2+, 24 hour urine must demonstrate &lt; or = 1 g of protein).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Surgery (including open biopsy), or radiotherapy within the last 4 weeks prior to first dose of bevacizumab or anticipation of interval cytoreductive surgery during study treatment2. Malignancies other than ovarian cancer within 5 years prior to randomisation, except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer3. Uncontrolled hypertension4. Current or recent (within 10 days of first dose of study treatment) use of aspirin &gt;325 mg/day5. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes (except for line patency).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer (web-based)</concealment>
    <sequence>1:1 ratio using stratified block randomisation stratifying for the following factors:FIGO stage, intent to start chemotherapy = or &gt; 4 weeks following surgery, and Gynaecologic Cancer Intergroup (GCIG) group.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>18/12/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1520</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Medical Research Council (UK)</primarysponsorname>
    <primarysponsoraddress>Medical Research Council
14th Floor
One Kemble Street
London 
WC2B 4AN</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Medical Research Council (UK)</fundingname>
      <fundingaddress>Medical Research Council
14th Floor
One Kemble Street
London 
WC2B 4AN</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>F. Hoffmann-La Roche</sponsorname>
      <sponsoraddress>C/- Medical Research Council
14th Floor
One Kemble Street
London 
WC2B 4AN</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the ICON 7 study is to evaluate the safety and efficacy of adding bevacizumab, a humanised monoclonal antibody against Vascular Endothelial Growth Factor (VEGF), to standard chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer.</summary>
    <trialwebsite>www.icon7trial.org</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/03/2008</ethicapprovaldate>
      <hrec>HREC Ref. 07/RPAH/83</hrec>
      <ethicsubmitdate>10/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Adult Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercy Hospital For Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Philip Beale</name>
      <address>Sydney Cancer Centre
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 95155895</phone>
      <fax>+61 2 95191546</fax>
      <email>Philip.Beale@cs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Julie Martyn</name>
      <address>ANZGOG Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625092</phone>
      <fax>+61 2 95625094</fax>
      <email>jmartyn@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kim Gillies</name>
      <address>NHMRC Clinical Trials Centre
Locked Bag 77
CAMPERDOWN  NSW  1450
AUSTRALIA</address>
      <phone>+61 2 95625032</phone>
      <fax>+61 2 95625094</fax>
      <email>kgillies@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>